Patrick Pilie
机构: University of Texas MD Anderson Cancer Center
每年引用次数
引用次数
引用: 3,682
H-指数: 24
I10-指数 : 29
出版物: 105
Precision Medicine: Progress, Pitfalls, and Promises.
Patrick G. Pilié , Patricia M. LoRusso , Timothy A. Yap
Molecular Cancer Therapeutics 16 ( 12) 2641 -2644
2
2017
Germline genetic variants in men with prostate cancer and one or more additional cancers.
Patrick G Pilié , Anna M Johnson , Kristen L Hanson , Megan E Dayno
Cancer 123 ( 20) 3925 -3932
22
2017
State-of-the-art strategies for targeting the DNA damage response in cancer
Patrick G. Pilié , Chad Tang , Gordon B. Mills , Timothy A. Yap
Nature Reviews Clinical Oncology 16 ( 2) 81 -104
664
2019
Broadening the View of Germline Mutations in Kidney Cancer.
Patrick G. Pilié , Kathleen A. Cooney
JAMA Oncology 4 ( 9) 1235 -1236
2018
Genomic Instability in Kidney Cancer: Etiologies and Treatment Opportunities
Patrick G. Pilié
Kidney Cancer 3 ( 3) 143 -150
1
2019
Systematic Review: Perioperative Systemic Therapy for Metastatic Renal Cell Carcinoma.
Patrick G. Pilié , Eric Jonasch
Kidney cancer (Clifton, Va.) 1 ( 1) 57 -64
4
2017
Comprehensive Molecular Characterization Identifies Distinct Genomic and Immune Hallmarks of Renal Medullary Carcinoma
Pavlos Msaouel , Gabriel G. Malouf , Xiaoping Su , Hui Yao
Cancer Cell 37 ( 5)
55
2020
SET-ing the stage for PI3Kβ inhibitor sensitivity in clear cell renal cell carcinoma.
Patrick G. Pilié , Eric Jonasch
Oncotarget 10 ( 16) 1540 -1541
2019
PARP Inhibitors: Extending Benefit Beyond BRCA-Mutant Cancers
Patrick G. Pilié , Carl M. Gay , Lauren A. Byers , Mark J. O'Connor
Clinical Cancer Research 25 ( 13) 3759 -3771
74
2019
Adiposity and response to androgen signaling inhibition (ASI) in men with metastatic castration-resistant prostate cancer (mCRPC).
David R. Fogelman , Christopher Logothetis , Eleni Efstathiou , Michael W Starbuck
Journal of Clinical Oncology 39 72 -72
2021
Replication stress response deficiency (RSRD) and response to immune therapy in clear cell renal cell carcinoma (ccRCC).
Patrick Glen Pilie , Daniel James McGrail , Shiaw-Yih Lin , Eric Jonasch
Journal of Clinical Oncology 36 ( 15_suppl) 4566 -4566
2018
Functional biomarkers of homologous repair (HR) deficiency to guide novel DNA damage response targeted therapy in clear cell renal cell carcinoma (ccRCC).
Guang Peng , Eric Jonasch , Patrick Glen Pilie , Christine B Peterson
Journal of Clinical Oncology 36 4576 -4576
1
2018
Linking the Aggressive Variant Prostate Cancer (AVPC) molecular signature (-ms) to androgen indifference in a prospective clinical trial.
Paul Vincent Viscuse , Miao Zhang , Jingjing Liu , Rebecca Slack Tidwell
Journal of Clinical Oncology 38 156 -156
2020
Genomic instability and DNA damage repair in clear cell renal cell carcinoma.
Patrick Glen Pilie , Lijun Zhou , Pan Tong , Surena F. Matin
Journal of Clinical Oncology 35 4581 -4581
1
2017
Pilot study of dovitinib in patients with VHL disease.
Patrick Glen Pilie , Surena F. Matin , Ashley Henriksen Woodson , Valerie D. Marcott
Journal of Clinical Oncology 34 ( 2_suppl) 587 -587
1
2016
Real-world outcomes of genetic testing in a GU genetics clinic and evaluation of current guidelines.
Annelise Pace , Ashley Henriksen Woodson , Rebecca Slack-Tidwell , Molly S Daniels
Journal of Clinical Oncology 37 668 -668
2019
Correlation of pathogenic POLE mutations with clinical benefit to immune checkpoint inhibitor therapy.
Benjamin Garmezy , Jinesh S. Gheeya , Kyaw Zin Thein , Patrick Glen Pilie
Journal of Clinical Oncology 38 3008 -3008
2
2020
Homologous repair deficiency in VHL-mutated clear cell renal cell carcinoma.
Patrick Glen Pilie , Lijun Zhou , Christine B Peterson , Yang Peng
Journal of Clinical Oncology 36 585 -585
2
2018
Identifying functional loss of ATM gene in patients with advanced cancer.
Patrick Glen Pilie , Jinesh S. Gheeya , Keith Kyewalabye , Rohit Vivek Goswamy
Journal of Clinical Oncology 38 3629 -3629
2020
Third analysis of a randomized trial of finite abiraterone acetate (AA) plus LHRH agonist (LHRHa) versus LHRHa in biochemically recurrent, non-metastatic hormone-naïve prostate cancer (M0HNPC).
Andrew Warren Hahn , Xuemei Wang , Eleni Efstathiou , Hyunsoo Hwang
Journal of Clinical Oncology 40 ( 6_suppl) 135 -135
2022